{"id":"NCT00252564","sponsor":"US Oncology Research","briefTitle":"Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer","officialTitle":"Randomized PhIII Trial of Cetuximab, Bevacizumab & Biweekly Infusional 5FU/Leucovorin (FOLF-CB) vs. Oxaliplatin, Bevacizumab, & Biweekly Infusional 5FU/Leucovorin (Bev-FOLFOX) in First Line Treatment of Metastatic Colorectal Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-09","primaryCompletion":"2007-06","completion":"2009-06","firstPosted":"2005-11-11","resultsPosted":"2011-03-14","lastUpdate":"2019-02-15"},"enrollment":247,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Colorectal Cancer"],"interventions":[{"type":"DRUG","name":"Bevacizumab","otherNames":["Avastin"]},{"type":"DRUG","name":"Oxaliplatin","otherNames":["Eloxatin"]},{"type":"DRUG","name":"Leucovorin","otherNames":[]},{"type":"DRUG","name":"Fluorouracil","otherNames":["5FU"]},{"type":"DRUG","name":"Cetuximab","otherNames":["Erbitux"]}],"arms":[{"label":"Bev-FOLFOX","type":"EXPERIMENTAL"},{"label":"FOLF-CB","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to compare the rates of Progression-Free Survival (PFS) at 12 months for patients treated with Bev-FOLFOX versus patients treated with FOLF-CB for first line treatment of metastatic colorectal cancer.","primaryOutcome":{"measure":"Progression-Free Survival (PFS)","timeFrame":"12 months","effectByArm":[{"arm":"Arm A","deltaMin":11,"sd":null},{"arm":"Arm B","deltaMin":8.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":15,"exclusionCount":23},"locations":{"siteCount":82,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":40,"n":118},"commonTop":["NAUSEA","DIARRHEA","RASH","FATIGUE","NEUROPATHY"]}}